Tiziana Life Sciences PLC Sponsored ADR Stock News

Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi talked with Proactive about the company's latest milestone: dosing the first patient in its Phase 2a clinical trial targeting multiple system atrophy (MSA), a rare and fatal neurodegenerative condition with no approved treatment. Elrifi explained the trial involves the company's investigational monoclonal antibody, Foralumab, which is admi...

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has enrolled and dosed the first participant in its Phase 2a clinical trial evaluating intranasal foralumab in patients with Multiple System Atrophy (MSA).   The trial is being conducted at Brigham and Women's Hospital in Boston, Massachusetts.

BOSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the first participant has been enrolled and dosed in its Phase 2a clinical trial e...

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the US Food & Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its Phase 2a clinical trial of intranasal foralumab in patients with Multiple System Atrophy (MSA). The Phase 2a study is a six-month, open-label clinical trial designed to evaluate the effects of intranasal foralumab on microglial activa...

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, is pleased to announce that the U.S. Food & Drug Administration (FDA) have approved the IND for its P...

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said that its experimental nasal treatment for Alzheimer's disease showed promising results in a patient, helping reduce brain inflammation and possibly aiding in the removal of harmful protein buildup linked to the disease. The company's lead drug, intranasal foralumab, is a fully human antibody designed to regulate the immune system.

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced compelling immunologic findings from the treatment of a moderate Alzheimer's Disease ...

Tiziana is developing foralumab, a fully human anti-CD3 monoclonal antibody, for non-active secondary progressive multiple sclerosis patients, with key data expected in 2026. A phase 2 trial of foralumab in early-stage Alzheimer's Disease is set to begin in 2025, targeting microglial activation and neuroinflammation. The global Alzheimer's Disease market is expected to reach $23.8 billion by 2031.